NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-11
DOI
10.1038/s41467-019-08530-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive ADP‐ribosylome analysis identifies tyrosine as an ADP‐ribose acceptor site
- (2018) Deena M Leslie Pedrioli et al. EMBO REPORTS
- Serine ADP-Ribosylation Depends on HPF1
- (2017) Juan José Bonfiglio et al. MOLECULAR CELL
- The role of poly ADP-ribosylation in the first wave of DNA damage response
- (2017) Chao Liu et al. NUCLEIC ACIDS RESEARCH
- NAD+ Kinase as a Therapeutic Target in Cancer
- (2016) P. M. Tedeschi et al. CLINICAL CANCER RESEARCH
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
- (2016) Angela George et al. Nature Reviews Clinical Oncology
- ADPriboDB: The database of ADP-ribosylated proteins
- (2016) Christina A. Vivelo et al. NUCLEIC ACIDS RESEARCH
- Functional annotation of rare gene aberration drivers of pancreatic cancer
- (2016) Yiu Huen Tsang et al. Nature Communications
- PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2BGlu2
- (2016) Gabrielle J. Grundy et al. Nature Communications
- Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue
- (2016) Rita Martello et al. Nature Communications
- Functions of PARylation in DNA Damage Repair Pathways
- (2016) Huiting Wei et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging
- (2016) Matthias Altmeyer et al. Aging-US
- Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs
- (2016) Ryan C. Dregalla et al. Aging-US
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- The Promise of Proteomics for the Study of ADP-Ribosylation
- (2015) Casey M. Daniels et al. MOLECULAR CELL
- PARP-2 domain requirements for DNA damage-dependent activation and localization to sites of DNA damage
- (2015) Amanda A. Riccio et al. NUCLEIC ACIDS RESEARCH
- NAD+ in aging, metabolism, and neurodegeneration
- (2015) E. Verdin SCIENCE
- ARTD1 (PARP1) activation and NAD+ in DNA repair and cell death
- (2014) Elise Fouquerel et al. DNA REPAIR
- The ADP-ribosyltransferase PARP10/ARTD10 Interacts with Proliferating Cell Nuclear Antigen (PCNA) and Is Required for DNA Damage Tolerance
- (2014) Claudia M. Nicolae et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Family-wide analysis of poly(ADP-ribose) polymerase activity
- (2014) Sejal Vyas et al. Nature Communications
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Proteome-wide Identification of Poly(ADP-Ribosyl)ation Targets in Different Genotoxic Stress Responses
- (2013) Stephanie Jungmichel et al. MOLECULAR CELL
- SIRT6 Recruits SNF2H to DNA Break Sites, Preventing Genomic Instability through Chromatin Remodeling
- (2013) Debra Toiber et al. MOLECULAR CELL
- BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
- (2013) Britta Stordal et al. Molecular Oncology
- Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome
- (2013) Yajie Zhang et al. NATURE METHODS
- Structural Implications for Selective Targeting of PARPs
- (2013) Jamin D. Steffen et al. Frontiers in Oncology
- The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
- (2012) Mike De Vos et al. BIOCHEMICAL PHARMACOLOGY
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
- (2012) X. Luo et al. GENES & DEVELOPMENT
- HMGN1 Protein Regulates Poly(ADP-ribose) Polymerase-1 (PARP-1) Self-PARylation in Mouse Fibroblasts
- (2012) Aya Masaoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
- (2011) C. Boehler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
- (2010) Elizabeth A. Comen et al. CANCER JOURNAL
- The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction
- (2010) Marie-France Langelier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Making the best of PARP inhibitors in ovarian cancer
- (2010) Susana Banerjee et al. Nature Reviews Clinical Oncology
- Toward a unified nomenclature for mammalian ADP-ribosyltransferases
- (2010) Michael O. Hottiger et al. TRENDS IN BIOCHEMICAL SCIENCES
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
- (2009) W. Sakai et al. CANCER RESEARCH
- Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites
- (2009) Matthias Altmeyer et al. NUCLEIC ACIDS RESEARCH
- Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation
- (2008) Henning Kleine et al. MOLECULAR CELL
- Nampt: linking NAD biology, metabolism and cancer
- (2008) Antje Garten et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- NAD+/NADH and NADP+/NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences
- (2007) Weihai Ying ANTIOXIDANTS & REDOX SIGNALING
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started